Homepage
Author:
Cognition Therapeutics, Inc.
Posted Date:
April 7, 2026
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
Cognition Therapeutics, Inc.
April 7, 2026
Cognition Therapeutics CEO Issues Letter to Shareholders
Cognition Therapeutics, Inc.
March 31, 2026
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
Cognition Therapeutics, Inc.
March 26, 2026
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
Cognition Therapeutics, Inc.
March 23, 2026
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
Cognition Therapeutics, Inc.
March 17, 2026
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
Cognition Therapeutics, Inc.
March 2, 2026
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Cognition Therapeutics, Inc.
February 8, 2026
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
Cognition Therapeutics, Inc.
January 28, 2026
